2022
33120 Early and sustained improvement in atopic dermatitis (AD) disease control and treatment satisfaction with dupilumab in clinical practice: Long-term data from the RELIEVE-AD study
Strober B, Chao J, Chuang C. 33120 Early and sustained improvement in atopic dermatitis (AD) disease control and treatment satisfaction with dupilumab in clinical practice: Long-term data from the RELIEVE-AD study. Journal Of The American Academy Of Dermatology 2022, 87: ab47. DOI: 10.1016/j.jaad.2022.06.221.Peer-Reviewed Original Research
2010
The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.
Levine D, Strober B. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics. Seminars In Cutaneous Medicine And Surgery 2010, 29: 28-34. PMID: 20430305, DOI: 10.1016/j.sder.2010.02.003.Peer-Reviewed Original ResearchConceptsSevere psoriasisUS FoodDrug AdministrationTumor necrosis factor-alpha inhibitorsNecrosis factor-alpha inhibitorsInterleukin-12/23 inhibitorsShort-term safetyT-cell modulatorDevelopment of biologicsBiologic therapyPsoriasis patientsPsoriatic patientsClinical trialsTherapeutic monitoringSpecific patientPatientsBiologicsMedicationsPsoriasisLong-term dataAdministrationTreatmentCurrent bodyInhibitorsEvidence